Cytokinetics (CYTK) Gains from Sales and Divestitures (2016 - 2017)
Historic Gains from Sales and Divestitures for Cytokinetics (CYTK) over the last 6 years, with Q4 2017 value amounting to $171250.0.
- Cytokinetics' Gains from Sales and Divestitures rose 27431.69% to $171250.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $171250.0, marking a year-over-year increase of 27431.69%. This contributed to the annual value of $171250.0 for FY2017, which is 27431.69% up from last year.
- According to the latest figures from Q4 2017, Cytokinetics' Gains from Sales and Divestitures is $171250.0, which was up 27431.69% from $45750.0 recorded in Q4 2016.
- Cytokinetics' Gains from Sales and Divestitures' 5-year high stood at $211897.0 during Q3 2013, with a 5-year trough of $20833.0 in Q4 2014.
- Its 5-year average for Gains from Sales and Divestitures is $117284.2, with a median of $108500.0 in 2016.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first plummeted by 9016.83% in 2014, then surged by 27431.69% in 2017.
- Quarter analysis of 5 years shows Cytokinetics' Gains from Sales and Divestitures stood at $211897.0 in 2013, then tumbled by 90.17% to $20833.0 in 2014, then surged by 101.98% to $42078.0 in 2015, then increased by 8.73% to $45750.0 in 2016, then surged by 274.32% to $171250.0 in 2017.
- Its last three reported values are $171250.0 in Q4 2017, $45750.0 for Q4 2016, and $42078.0 during Q4 2015.